<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05047133</url>
  </required_header>
  <id_info>
    <org_study_id>1722787-1</org_study_id>
    <nct_id>NCT05047133</nct_id>
  </id_info>
  <brief_title>Effect of Early Administration of TXA in Adult Hip Fractures</brief_title>
  <official_title>Does Early Administration of Tranexamic Acid Decrease Perioperative Blood Loss in Addition to Intraoperative Tranexamic Acid for Hip Fracture Patients?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascension Genesys Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ascension Genesys Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective clinical study designed to assess blood loss in intracapsular and&#xD;
      extracapsular hip fractures undergoing operative fixation at a Level II trauma center. It is&#xD;
      well established in the orthopedic literature that tranexamic acid (TXA) decreases blood loss&#xD;
      and need for postoperative blood transfusion in hip fracture patients as well as total joint&#xD;
      arthroplasty patients. A typical dosing pattern, and the dosing pattern employed at our&#xD;
      institution, is 1 gram IV infused prior to incision followed by 1 gram IV infused at the time&#xD;
      of wound closure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative Blood Transfusion</measure>
    <time_frame>Up to two weeks</time_frame>
    <description>Patient receives a blood transfusion during their postoperative stay in the hospital</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Blood Loss</measure>
    <time_frame>Up to two weeks</time_frame>
    <description>Calculate the difference in postoperative blood loss between groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>Up to two weeks</time_frame>
    <description>Overall length of hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Pain</measure>
    <time_frame>Up to two weeks</time_frame>
    <description>Difference in overall pain scores between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound complications</measure>
    <time_frame>Up to two weeks</time_frame>
    <description>Acute wound complications documented after surgical intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute DVT/PE</measure>
    <time_frame>Up to two weeks</time_frame>
    <description>Documented deep venous thrombosis or pulmonary embolism</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Postoperative Blood Loss</condition>
  <arm_group>
    <arm_group_label>Early Adminstration of TXA + Intraoperative TXA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group receives 1 G of TXA as soon as possible after a diagnosis of an acute hip fracture if the patient meets inclusion and exclusion criteria. The group will also receive 2 grams of TXA total intraoperatively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intraoperative only TXA</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This group will only receive the intraoperative TXA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid</intervention_name>
    <description>TXA to be given at time of diagnosis in the emergency department (ED) in treatment group and at time of operation for both groups</description>
    <arm_group_label>Early Adminstration of TXA + Intraoperative TXA</arm_group_label>
    <arm_group_label>Intraoperative only TXA</arm_group_label>
    <other_name>Lysteda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. All adult (18 years old or older) hip fracture patients presenting with an acute&#xD;
             hip fracture and undergoing operative fixation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Polytrauma patients&#xD;
&#xD;
          2. Previous operation on the ipsilateral hip&#xD;
&#xD;
          3. Patients with coagulopathies (Factor V Leiden, Sickle Cell Anemia, Etc.)&#xD;
&#xD;
          4. Patients with &lt; 6-month history of thromboembolic event (DVT/PE), Stroke, Cardiac&#xD;
             Stents, or Myocardial Infarction (MI)&#xD;
&#xD;
          5. History of seizure disorder&#xD;
&#xD;
          6. Patients on birth control&#xD;
&#xD;
          7. Pregnant Women&#xD;
&#xD;
          8. Prisoners&#xD;
&#xD;
          9. Active thromboembolic disease (DVT/PE, MI, Stroke)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jacob Hinkley, DO, MS</last_name>
    <phone>810-606-5669</phone>
    <email>jacob.hinkley2@ascension.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jacob Lytle, DO</last_name>
    <phone>810-606-5669</phone>
    <email>jacob.lytle@ascension.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ascension Genesys Hospital</name>
      <address>
        <city>Grand Blanc</city>
        <state>Michigan</state>
        <zip>48439</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Watt, MS, BSN</last_name>
      <phone>810-606-7713</phone>
      <email>sandra.watt@ascension.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 3, 2021</study_first_submitted>
  <study_first_submitted_qc>September 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ascension Genesys Hospital</investigator_affiliation>
    <investigator_full_name>Jacob Hinkley</investigator_full_name>
    <investigator_title>Resident Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postoperative Hemorrhage</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

